---
title: "CSPC Pharmaceutical Receives US$15 Million Milestone Payment Under Corbus License Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306093004.md"
description: "CSPC Megalith, a subsidiary of CSPC Pharmaceutical Group, received a $15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. This payment brings the total upfront and milestone payments under their exclusive license agreement to $32.5 million. The deal grants Corbus exclusive rights to develop and commercialize CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4."
datetime: "2026-11-19T09:17:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306093004.md)
  - [en](https://longbridge.com/en/news/306093004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306093004.md)
generator: "portal-rs"
---

# CSPC Pharmaceutical Receives US$15 Million Milestone Payment Under Corbus License Deal

-   CSPC Pharmaceutical Group subsidiary CSPC Megalith received a USD 15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. \* Total upfront and development milestone payments under the exclusive license agreement reached USD 32.5 million. \* The agreement grants Corbus exclusive development and commercialization rights to CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261119-12418440), on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC PHARMA  Receives USD15 million Development Milestone Payment for CRB-701](https://longbridge.com/en/news/306095007.md)
- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [Corbus' CRB-913 shows 5% mean weight loss at 12 weeks in Phase 1b trial](https://longbridge.com/en/news/305675255.md)
- [CICC: CSPC PHARMA  3Q Results In Line, Core Business Remains Solid](https://longbridge.com/en/news/306221587.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**